1136 terminated. 1136 Phase 2, 328 Phase 1, 30 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1136 | Terminated 1136 |
| Phase 1 | 328 | Terminated 328 |
| Phase 3 | 30 | Terminated 30 |
Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Extension Study to Pioneer Study 6058-SCD-101 Pociredir - Sickle Cell Disease | Phase 2 | Terminated | Fulcrum Therapeutics | 1 | 2026-03-30 | 2026-10-28 |
| Multiple CAR-T Cell Therapy Targeting AML CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2025-08-01 | 2026-11-02 |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-08-01 | 2026-10-30 |
| A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML S227928, Venetoclax - Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML | Phase 1 / Phase 2 | Terminated | Servier Bio-Innovation LLC | 13 | 2025-02-25 | 2026-03-30 |
| BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult | Phase 1 / Phase 2 | Terminated | BlueSphere Bio, Inc | 2 | 2025-02-04 | 2026-09-10 |
| BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B BE-101 - Hemophilia B, Hemophilia B, Moderately Severe or Severe | Phase 1 / Phase 2 | Terminated | Be Biopharma | 5 | 2024-12-04 | 2026-06-15 |
| Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML Luveltamab tazevibulin - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Terminated | Sutro Biopharma, Inc. | 1 | 2024-12-04 | 2026-10-13 |
| Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization Anti-(integrin beta-3) human monoclonal antibody - Fetal and Neonatal Alloimmune Thrombocytopenia | Phase 2 | Terminated | Rallybio | 1 | 2024-11-21 | 2026-03-06 |
| Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy - Severe Aplastic Anemia, Cyclophosphamide Reduced-dose | Phase 2 | Terminated | Institute of Hematology & Blood Diseases Hospital, China | 14 | 2024-11-01 | 2026-11-04 |
| RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis RVU120, Ruxolitinib - Myelofibrosis | Phase 2 | Terminated | Ryvu Therapeutics SA | 36 | 2024-09-19 | 2026-09-16 |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Terminated | Centre Leon Berard | 1 | 2024-09-11 | 2025-02-20 |
| A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies SAR443579, venetoclax, azacitidine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Sanofi | 7 | 2024-08-13 | 2026-10-19 |
| ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency INZ-701 - Gene Mutations, Pseudoxanthoma Elasticum | Phase 2 | Terminated | Inozyme Pharma | 22 | 2024-06-19 | 2026-10-19 |
| A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) TQ05105 tablets, TQB3909 tablets - Myelofibrosis | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 21 | 2024-05-13 | 2026-01-05 |
| Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML RVU120 - Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | Phase 2 | Terminated | Ryvu Therapeutics SA | 62 | 2024-01-23 | 2026-09-16 |
| Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant VCAR33 - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Terminated | Vor Biopharma | 38 | 2023-12-11 | 2025-07-29 |
| A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma Forimtamig, Carfilzomib, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 21 | 2023-12-08 | 2026-09-29 |
| Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2023-11-14 | 2025-12-02 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia VLX-1005, Placebo - Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia | Phase 2 | Terminated | Veralox Therapeutics | 24 | 2023-09-26 | 2025-11-25 |
Showing 20 of 1136. Sign in to see all of them.
Multiple Myeloma (247) · Leukemia, Myeloid, Acute (239) · Leukemia (184) · Myelodysplastic Syndromes (182) · Leukemia, Lymphocytic, Chronic, B-Cell (156) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (131) · Lymphoma (92) · Lymphoma, Non-Hodgkin (89) · Recurrence (78) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (72) · Hematologic Neoplasms (59) · Lymphoma, Large B-Cell, Diffuse (57) · Lymphoma, Follicular (55) · Anemia (54) · Lymphoma, Mantle-Cell (50)
Hemic and Lymphatic Diseases (1136) · Neoplasms (820) · Neoplasms by Histologic Type (806) · Immune System Diseases (592) · Immunoproliferative Disorders (547) · Lymphoproliferative Disorders (534) · Leukemia (389) · Pathological Conditions, Signs and Symptoms (386) · Pathologic Processes (379) · Lymphatic Diseases (349) · Hemorrhagic Disorders (336) · Disease Attributes (332) · Bone Marrow Diseases (324) · Leukemia, Myeloid (311)
Cyclophosphamide (104) · Dexamethasone (90) · Cytarabine (70) · Rituximab (69) · fludarabine (68) · fludarabine phosphate (66) · Bortezomib (56) · Azacitidine (53) · Lenalidomide (51) · Calcium Dobesilate (45) · Busulfan (43) · Methotrexate (40) · Whole-Body Irradiation (40) · Filgrastim (39) · Melphalan (39)
M.D. Anderson Cancer Center (83) · National Cancer Institute (NCI) (41) · Masonic Cancer Center, University of Minnesota (27) · Novartis Pharmaceuticals (27) · Fred Hutchinson Cancer Center (22) · Mayo Clinic (16) · Gilead Sciences (15) · Weill Medical College of Cornell University (15) · Incyte Corporation (13) · OHSU Knight Cancer Institute (13) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (13) · Washington University School of Medicine (13) · St. Jude Children's Research Hospital (12) · Baylor College of Medicine (11) · Emory University (10)
United States (880) · France (100) · Italy (92) · United Kingdom (83) · Germany (82) · Spain (79) · Canada (71) · Australia (46) · Belgium (35) · Netherlands (31) · South Korea (31) · Poland (26) · Denmark (24) · China (23) · Austria (21)
Courtney DiNardo, MD (5) · Jorge Cortes, MD (5) · Guillermo Garcia-Manero, MD (4)
PMID 39903535, PMID 32031570, PMID 32171076, PMID 29515037, PMID 35622074, PMID 23053510, PMID 26472751, PMID 28835440, PMID 30885996, PMID 31527168, PMID 34398557, PMID 35857660, PMID 36791280, PMID 41671463, PMID 42749863, PMID 10499616, PMID 11071652, PMID 11222401, PMID 12011123, PMID 12637486, PMID 12791647, PMID 1348362, PMID 14550808, PMID 14551141, PMID 15381930, PMID 15486072, PMID 16304375, PMID 16403905, PMID 16609072, PMID 16622268, PMID 16651647, PMID 1707752, PMID 17579184, PMID 17602062, PMID 17611569, PMID 18463354, PMID 18946659, PMID 19118065, PMID 19139736, PMID 19179301, PMID 19826119, PMID 20059562, PMID 20067838, PMID 20307284, PMID 21145590, PMID 21275961, PMID 21381892, PMID 21403127, PMID 21420732, PMID 21527519
2018 (18), P30CA015704 (14), 2016 (10), 2019 (10), 2017 (9), P30CA015083 (9), 2014 (8), P30CA016672 (8), 2008 (7), 2023 (7), 2009 (6), U10CA021115 (6), 2015 (4), P01CA018029 (4), P30CA006973 (4)